Durect Corp (FRA:DC8A)
€ 0.81 -0.015 (-1.88%) Market Cap: 25.87 Mil Enterprise Value: 29.05 Mil PE Ratio: 0 PB Ratio: 22.56 GF Score: 60/100

DURECT Corp at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 15, 2023 / 06:00PM GMT
Release Date Price: €4.42 (-0.45%)
Francois Brisebois
Oppenheimer & Co. Inc. - Analyst

Okay, great. Hi, everyone. My name is Francois Brisebois. I'm one of the biotech analysts at Oppenheimer. Thanks for joining on day three of the healthcare conference. I know it has been messy in the market and with the weather as well for some people so appreciate you taking the time to join us today.

The next presenter here would be DURECT Corporation. DURECT is a company that we cover at AHFIRM with an outperform rating, a big, big year for the company, with important data readout later this year in alcoholic hepatitis or alcohol-associated hepatitis. I think we've changed the name to that.

So from the team, we have CEO, Jim Brown; we have CMO, Chief Medical Officer, Dr. Norman Sussman; we have CFO, Tim Papp; and we also have Senior VP -- sorry, yes, Senior VP, Business Development and Commercial with Keith Lui. So -- which should be helpful to have everyone on here.

Questions & Answers

Francois Brisebois
Oppenheimer & Co. Inc. - Analyst

So what we'll do in terms of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot